期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 3, 期 77, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3002369
关键词
-
资金
- NIA NIH HHS [R37 AG013956-16, R01 AG016208, P50 AG005681, P01 AG003991, U01 AG032438-04, P01 AG026276-05, P01 AG003991-29, R01 AG035083, R01 AG016208-11, RC1 AG035654-02, R37 AG013956, RC1 AG035654, R01 AG035083-02, P01 AG026276, P50 AG005681-28, U01 AG032438] Funding Source: Medline
Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 years have changed the way we think about AD. This review discusses some of the challenges to translating these basic molecular and cellular discoveries into clinical therapies. Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据